IL17A and COVID-19: (2021) identified a likely risk of developing prolonged symptoms of COVID-19 in hospitalized patients, noting that convalescent patients had a lower frequency of IL-10+ CD4+ T cells, IL-17+ CD4+ T cells, and IL-6+ B cells, compared to individuals with acute COVID-19.